文献速递哮喘

哮喘患者骨质疏松与脆性骨折发生率:英国人群匹配队列研究

Incidence of osteoporosis and fragility fractures in asthma: a UK population-based matched cohort study.
PubMed 文献 · Eur Respir J · 2021-01-21

该研究基于英国临床实践研究数据库开展匹配队列研究,比较哮喘成人(按年龄、性别和诊所匹配最多4名无哮喘者)与一般人群的骨质疏松和脆性骨折发生率。结果显示哮喘患者骨质疏松风险升高(aHR 1.18,95%CI 1.13-1.23),脆性骨折风险增加12%(aHR 1.12,95%CI 1.07-1.16),且年龄修饰该效应(交互作用P<0.0001),年轻人群效应更强;口服糖皮质激素与骨质疏松呈剂量反应关系,每年≥6个疗程时脆性骨折风险增加,规律使用吸入糖皮质激素也增加两种骨病风险。

要点

  • 哮喘患者骨质疏松风险升高(aHR 1.18),脆性骨折风险增加12%(aHR 1.12)。
  • 年龄修饰效应,年轻哮喘患者骨病风险相对更高(交互作用P<0.0001)。
  • 口服糖皮质激素与骨质疏松呈剂量反应关系,每年≥6疗程增加脆性骨折风险。

核心结论

  • 哮喘患者较一般人群更易发生骨质疏松和脆性骨折,年轻人和频繁使用口服及吸入糖皮质激素者尤需关注。

研究设计与样本

  • 英国临床实践研究数据库(CPRD)匹配队列研究,成人新发哮喘患者按年龄、性别和诊所匹配最多4名无哮喘者。

主要发现

  • 哮喘患者骨质疏松风险升高(aHR 1.18,95%CI 1.13-1.23),脆性骨折风险增加12%(aHR 1.12,95%CI 1.07-1.16)。
  • 年龄修饰哮喘对骨质疏松和脆性骨折的效应,年轻人群效应更强(交互作用P<0.0001)。
  • 椎体(aHR 1.40,95%CI 1.33-1.48)和前臂/腕部(aHR 1.27,95%CI 1.22-1.32)是与较高发生率相关的部位。
  • 口服糖皮质激素与骨质疏松呈剂量反应关系,每年≥6个疗程者脆性骨折风险增加。
  • 规律使用吸入糖皮质激素增加骨质疏松和脆性骨折两种骨病风险。

临床怎么用

  • 对哮喘患者应评估骨质疏松和脆性骨折风险,尤其年轻患者及频繁使用口服或吸入糖皮质激素者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Osteoporosis and fragility fractures are associated with corticosteroids which are the mainstay treatment for asthma; however, these bone comorbidities within asthma need to be better described. METHODS: A matched cohort study was conducted using the UK Clinical Practice Research Database (CPRD). Adults with an incident asthma code were identified and matched, with up to four randomly selected people without asthma, by age, sex and practice. Osteoporosis and fragility fracture incidence rates were calculated, and Cox regression was performed comparing hazard rates to the general population. We report the impact of age, sex, glucocorticoids and the risk of specific fractures. RESULTS: Patients with asthma had a higher risk of osteoporosis (adjusted hazard ratio (aHR) 1.18, 95% CI 1.13-1.23) and were 12% (aHR 1.12, 95% CI 1.07-1.16) more likely to sustain fragility fractures than the general population. Age modified the effect of asthma on osteoporosis and fragility fractures, such that the effect was stronger in younger people (pinteraction<0.0001). The vertebra (aHR 1.40, 95% CI 1.33-1.48) and forearm/wrist (aHR 1.27, 95% CI 1.22-1.32) were the sites linked with a larger incidence. A dose-response relationship between oral corticosteroids (OCS) and osteoporosis was observed, whereas the risk of fragility fractures increased in those with six or more OCS courses per year. Regular use of inhaled corticosteroids (ICS) increased the risk of both bone conditions. CONCLUSIONS: Patients with asthma are more likely to develop osteoporosis or sustain fragility fractures than the general population, with a particular concern in younger people and those more frequently using OCS and ICS.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Chalitsios CV, McKeever TM, Shaw DE, et al. Incidence of osteoporosis and fragility fractures in asthma: a UK population-based matched cohort study. Eur Respir J. 2021. PMID: 32764111. doi:10.1183/13993003.01251-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。